Potential limitations of electronic database studies of prescription non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) and risk of myocardial infarction (MI)

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 8, 2005, Pages 513-522

  Ilkhanoff, Leonard ^a   Lewis, James D ^b   Hennessy, Sean ^b   Berlin, Jesse A ^b,c   Kimmel, Stephen E ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Bias; Myocardial infarction; Non aspirin non steroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; BODY MASS; CASE CONTROL STUDY; CIGARETTE SMOKING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DISEASE ASSOCIATION; DRUG UTILIZATION; EDUCATION; FAMILY HISTORY; HEART INFARCTION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; PHYSICAL ACTIVITY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BIAS (EPIDEMIOLOGY); BODY MASS INDEX; DATABASES, FACTUAL; EDUCATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; MYOCARDIAL INFARCTION; ODDS RATIO; PRESCRIPTIONS, DRUG; RISK ASSESSMENT;

EID: 23844543775     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1129     Document Type: Article

References (28)

1. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136: 161-172.
2. Schafer AI. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995; 35: 209-219.
3. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000; 11: 382-387.
4. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004; 109: 3000-3006.
5. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359: 118-123.
6. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-1073.
7. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099-1104.
8. Schlienger RG, Jick H, Meier CR. Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol 2002; 54: 327-332.
9. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002; 162: 1111-1115.
10. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162: 1105-1110.
11. Kimmel SE, Berlin JA, Reilly M, et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 2004; 43: 985-990.
12. Kimmel SE, Lewis JD, Jaskowiak J, Kishel L, Hennessy S. Enhancement of medication recall using medication pictures and lists in telephone interviews. Pharmacoepidemiol Drug Safe 2003; 12: 1-8.
13. Kleinbaum DG, Kupper LL, Morgenstern H. Information Bias. Epidemiologic Research: Principles and Quantitative Methods. Lifetime Learning Publications: Belmont, California, 1982; 242-265.
14. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989; 129: 125-137.
15. Fischer LM, Schlienger RG, Matter CM, Jick H, Meier CR. Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med 2004; 164: 2472-2476.
16. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021-2029.
17. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888-1899.
18. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000; 151: 488-496.
19. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289-300.
20. Brochier ML. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. Eur Heart J 1993; 14: 951-957.
21. Fornaro G, Rossi P, Mantica PG, et al. Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study. Circulation 1993; 87: 162-164.
22. Lewis JD, Localio RA, Kimmel SE, et al. Frequency of use influences recall of NSAID exposure. Abstract 005. Pharmacoepidemiol Drug Safe 2004; 13: S3.
23. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone Survey. JAMA 2002; 287: 337-344.
24. Wilcox CM, Shalek KA, Cotsonis G. Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage. Arch Intern Med 1994; 154: 42-46.
25. Inman WHW (ed.). Monitoring for Drug Safety. MTP Press Limited: Hingam, 1986; 223.
26. Use of Non-Steroidal Anti-Inflammatory Drugs Suspended in Large Alzheimer's Disease Prevention Trial. Assessed at http://www.nih.gov/news/pr/dec2004/od-20.htm on 4 January 2005.
27. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal MI. Ann Intern Med 2005; 142: 157-164.
28. Antithrombotic TC. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.